Logo image of SGMO

SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD

1.275  +0.03 (+2.82%)

Fundamental Rating

2

Overall SGMO gets a fundamental rating of 2 out of 10. We evaluated SGMO against 572 industry peers in the Biotechnology industry. The financial health of SGMO is average, but there are quite some concerns on its profitability. SGMO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SGMO had negative earnings in the past year.
In the past year SGMO has reported a negative cash flow from operations.
SGMO had negative earnings in each of the past 5 years.
In the past 5 years SGMO reported 4 times negative operating cash flow.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

SGMO has a worse Return On Assets (-165.31%) than 86.90% of its industry peers.
SGMO's Return On Equity of -470.00% is on the low side compared to the rest of the industry. SGMO is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
ROA -165.31%
ROE -470%
ROIC N/A
ROA(3y)-71.61%
ROA(5y)-48.53%
ROE(3y)-141.25%
ROE(5y)-94.01%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SGMO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SGMO has been increased compared to 5 years ago.
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

SGMO has an Altman-Z score of -20.87. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SGMO (-20.87) is worse than 87.26% of its industry peers.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.87
ROIC/WACCN/A
WACC10.71%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

SGMO has a Current Ratio of 1.35. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
SGMO has a worse Current ratio (1.35) than 83.36% of its industry peers.
SGMO has a Quick Ratio of 1.35. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.35, SGMO is doing worse than 82.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.28% over the past year.
Looking at the last year, SGMO shows a very negative growth in Revenue. The Revenue has decreased by -73.80% in the last year.
Measured over the past years, SGMO shows a quite strong growth in Revenue. The Revenue has been growing by 15.84% on average per year.
EPS 1Y (TTM)48.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.78%
Revenue 1Y (TTM)-73.8%
Revenue growth 3Y14.24%
Revenue growth 5Y15.84%
Sales Q2Q%425.77%

3.2 Future

Based on estimates for the next years, SGMO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.70% on average per year.
Based on estimates for the next years, SGMO will show a quite strong growth in Revenue. The Revenue will grow by 10.35% on average per year.
EPS Next Y67.56%
EPS Next 2Y34.01%
EPS Next 3Y22.15%
EPS Next 5Y18.7%
Revenue Next Year-67.76%
Revenue Next 2Y-41.55%
Revenue Next 3Y-18.45%
Revenue Next 5Y10.35%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as SGMO's earnings are expected to grow with 22.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.01%
EPS Next 3Y22.15%

More info and screens

0

5. Dividend

5.1 Amount

SGMO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (2/5/2025, 12:46:03 PM)

1.275

+0.03 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-19 2025-02-19/amc
Inst Owners42.09%
Inst Owner Change-0.07%
Ins Owners1.09%
Ins Owner Change-9.91%
Market Cap266.03M
Analysts78.57
Price Target5.27 (313.33%)
Short Float %11.07%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)108.08%
Min EPS beat(2)-21.11%
Max EPS beat(2)237.26%
EPS beat(4)1
Avg EPS beat(4)40.55%
Min EPS beat(4)-30.1%
Max EPS beat(4)237.26%
EPS beat(8)3
Avg EPS beat(8)17.65%
EPS beat(12)7
Avg EPS beat(12)16.54%
EPS beat(16)8
Avg EPS beat(16)9.91%
Revenue beat(2)1
Avg Revenue beat(2)37.1%
Min Revenue beat(2)-95.77%
Max Revenue beat(2)169.98%
Revenue beat(4)1
Avg Revenue beat(4)-23.5%
Min Revenue beat(4)-95.77%
Max Revenue beat(4)169.98%
Revenue beat(8)2
Avg Revenue beat(8)47.82%
Revenue beat(12)5
Avg Revenue beat(12)33.35%
Revenue beat(16)8
Avg Revenue beat(16)24.88%
PT rev (1m)-18.42%
PT rev (3m)35.97%
EPS NQ rev (1m)-7.35%
EPS NQ rev (3m)-128.12%
EPS NY rev (1m)0.53%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)30.43%
Revenue NQ rev (3m)4.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.04
P/FCF N/A
P/OCF N/A
P/B 6.8
P/tB 6.8
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.25
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.31%
ROE -470%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.61%
ROA(5y)-48.53%
ROE(3y)-141.25%
ROE(5y)-94.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.33%
Cap/Sales 5.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z -20.87
F-Score2
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)185.08%
Cap/Depr(5y)205.75%
Cap/Sales(3y)17.07%
Cap/Sales(5y)16.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.78%
EPS Next Y67.56%
EPS Next 2Y34.01%
EPS Next 3Y22.15%
EPS Next 5Y18.7%
Revenue 1Y (TTM)-73.8%
Revenue growth 3Y14.24%
Revenue growth 5Y15.84%
Sales Q2Q%425.77%
Revenue Next Year-67.76%
Revenue Next 2Y-41.55%
Revenue Next 3Y-18.45%
Revenue Next 5Y10.35%
EBIT growth 1Y-57.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.05%
EBIT Next 3Y26.79%
EBIT Next 5Y26.23%
FCF growth 1Y50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.89%
OCF growth 3YN/A
OCF growth 5YN/A